Just to further drill down on this, I did a Google search of "Teva Novopharm Lovenox" and found the following article that seems to imply that it is indeed Novopharm that is behind Teva's generic Lovenox: http://www.pharmaceutical-market-research.info/research/PMAAABIX-Injectable-Generic-Drugs--Prospects-and-Opportunities-to-2010.shtml . In particular, "Lovenox/Clexane (enoxaparin), with sales of over US$2.8 billion in 2005, of which US$1.6 billion was in the US. There have already been a number of ANDA applications for generic enoxaparin, including from Amphastar and Teva in 2003, which have been the subject of patent infringement litigation. More recently, Novopharm (Teva) and Momenta Pharmaceuticals have submitted ANDAs for generic enoxaparin."
So now, the big question assuming this article is accurate, how up to the task and ability is Novopharm in creating a generic Lovenox to the standards of MNTA?
Why do you say that? It's certainly in TEVA's interest to get it done, and I would expect they would use all resources available to make that happen sooner, rather than later?